Impact of statins on the coagulation status of type 2 diabetes patients evaluated by a novel thrombin-generation assay

P. Ferroni, D. Della-Morte, A. Pileggi, M. G. Valente, F. Martini, F. La Farina, R. Palmirotta, L. F. Meneghini, T. Rundek, C. Ricordi, F. Guadagni

Research output: Contribution to journalArticle

Abstract

Purpose Dyslipidemia is common in type 2 diabetes (T2D) and contributes to cardiovascular disease (CVD) by exacerbating atherosclerosis and hypercoagulability. Statins can stabilize atherosclerotic plaque and reduce prothrombotic status. In the present study we aimed to evaluate the coagulation activity and the effect of statins on procoagulant state of T2D patients using a novel activated protein C (APC)-dependent thrombin-generation assay. Methods Procoagulant status (by HemosIL ThromboPath (ThP) assay) and in vivo platelet activation (by plasma soluble (s)CD40L levels) were analyzed in a retrospective, cross-sectional study of 198 patients with long-standing T2D and 198 controls. Results Procoagulant status of T2D patients was enhanced when compared to control subjects (p

Original languageEnglish
Pages (from-to)301-309
Number of pages9
JournalCardiovascular Drugs and Therapy
Volume26
Issue number4
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Thrombin
Type 2 Diabetes Mellitus
CD40 Ligand
Thrombophilia
Platelet Activation
Atherosclerotic Plaques
Dyslipidemias
Protein C
Atherosclerosis
Cardiovascular Diseases
Cross-Sectional Studies

Keywords

  • Dyslipidemia
  • Haemostasis
  • Lipid-Lowering Drugs
  • Type 2 Diabetes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Impact of statins on the coagulation status of type 2 diabetes patients evaluated by a novel thrombin-generation assay. / Ferroni, P.; Della-Morte, D.; Pileggi, A.; Valente, M. G.; Martini, F.; La Farina, F.; Palmirotta, R.; Meneghini, L. F.; Rundek, T.; Ricordi, C.; Guadagni, F.

In: Cardiovascular Drugs and Therapy, Vol. 26, No. 4, 08.2012, p. 301-309.

Research output: Contribution to journalArticle

Ferroni, P. ; Della-Morte, D. ; Pileggi, A. ; Valente, M. G. ; Martini, F. ; La Farina, F. ; Palmirotta, R. ; Meneghini, L. F. ; Rundek, T. ; Ricordi, C. ; Guadagni, F. / Impact of statins on the coagulation status of type 2 diabetes patients evaluated by a novel thrombin-generation assay. In: Cardiovascular Drugs and Therapy. 2012 ; Vol. 26, No. 4. pp. 301-309.
@article{f9c118c1c50b429ca58c1a203fd74d51,
title = "Impact of statins on the coagulation status of type 2 diabetes patients evaluated by a novel thrombin-generation assay",
abstract = "Purpose Dyslipidemia is common in type 2 diabetes (T2D) and contributes to cardiovascular disease (CVD) by exacerbating atherosclerosis and hypercoagulability. Statins can stabilize atherosclerotic plaque and reduce prothrombotic status. In the present study we aimed to evaluate the coagulation activity and the effect of statins on procoagulant state of T2D patients using a novel activated protein C (APC)-dependent thrombin-generation assay. Methods Procoagulant status (by HemosIL ThromboPath (ThP) assay) and in vivo platelet activation (by plasma soluble (s)CD40L levels) were analyzed in a retrospective, cross-sectional study of 198 patients with long-standing T2D and 198 controls. Results Procoagulant status of T2D patients was enhanced when compared to control subjects (p",
keywords = "Dyslipidemia, Haemostasis, Lipid-Lowering Drugs, Type 2 Diabetes",
author = "P. Ferroni and D. Della-Morte and A. Pileggi and Valente, {M. G.} and F. Martini and {La Farina}, F. and R. Palmirotta and Meneghini, {L. F.} and T. Rundek and C. Ricordi and F. Guadagni",
year = "2012",
month = "8",
doi = "10.1007/s10557-012-6388-y",
language = "English",
volume = "26",
pages = "301--309",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Impact of statins on the coagulation status of type 2 diabetes patients evaluated by a novel thrombin-generation assay

AU - Ferroni, P.

AU - Della-Morte, D.

AU - Pileggi, A.

AU - Valente, M. G.

AU - Martini, F.

AU - La Farina, F.

AU - Palmirotta, R.

AU - Meneghini, L. F.

AU - Rundek, T.

AU - Ricordi, C.

AU - Guadagni, F.

PY - 2012/8

Y1 - 2012/8

N2 - Purpose Dyslipidemia is common in type 2 diabetes (T2D) and contributes to cardiovascular disease (CVD) by exacerbating atherosclerosis and hypercoagulability. Statins can stabilize atherosclerotic plaque and reduce prothrombotic status. In the present study we aimed to evaluate the coagulation activity and the effect of statins on procoagulant state of T2D patients using a novel activated protein C (APC)-dependent thrombin-generation assay. Methods Procoagulant status (by HemosIL ThromboPath (ThP) assay) and in vivo platelet activation (by plasma soluble (s)CD40L levels) were analyzed in a retrospective, cross-sectional study of 198 patients with long-standing T2D and 198 controls. Results Procoagulant status of T2D patients was enhanced when compared to control subjects (p

AB - Purpose Dyslipidemia is common in type 2 diabetes (T2D) and contributes to cardiovascular disease (CVD) by exacerbating atherosclerosis and hypercoagulability. Statins can stabilize atherosclerotic plaque and reduce prothrombotic status. In the present study we aimed to evaluate the coagulation activity and the effect of statins on procoagulant state of T2D patients using a novel activated protein C (APC)-dependent thrombin-generation assay. Methods Procoagulant status (by HemosIL ThromboPath (ThP) assay) and in vivo platelet activation (by plasma soluble (s)CD40L levels) were analyzed in a retrospective, cross-sectional study of 198 patients with long-standing T2D and 198 controls. Results Procoagulant status of T2D patients was enhanced when compared to control subjects (p

KW - Dyslipidemia

KW - Haemostasis

KW - Lipid-Lowering Drugs

KW - Type 2 Diabetes

UR - http://www.scopus.com/inward/record.url?scp=84864464224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864464224&partnerID=8YFLogxK

U2 - 10.1007/s10557-012-6388-y

DO - 10.1007/s10557-012-6388-y

M3 - Article

C2 - 22527619

AN - SCOPUS:84864464224

VL - 26

SP - 301

EP - 309

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 4

ER -